Search Results for agency_names:"Justice Department"

The Drug Enforcement Administration (DEA) issued an order to revoke the DEA registration of Robert Esser, D.D.S., from Erie, Pennsylvania, because his dental license is suspended, making him unable to legally handle controlled substances in Pennsylvania. Dr. Esser did not request a hearing to contest this, leading to his default according to DEA rules. The DEA has denied any pending applications for Dr. Esser to renew or modify his registration, effective January 29, 2025. Consequently, Dr. Esser is not permitted to dispense controlled substances as he does not meet the legal requirements set by the state and DEA regulations.

The Consortium for Execution of Rendezvous and Servicing Operations (CONFERS) has updated its membership and filed these changes with the Attorney General and the Federal Trade Commission. New members include ClearSpace SA from Switzerland and several U.S.-based companies, while Effective Space from the United Kingdom has left the group. The purpose of the filing is to extend the law that limits how much money can be recovered in antitrust lawsuits against CONFERS. The group plans to continue notifying about membership changes in the future.

PCI Synthesis has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of controlled substances. They plan to use these substances for developing manufacturing processes and conducting tests. The application has been filed under notice by the DEA, and comments or objections to this application can be submitted by April 19, 2021. Additionally, PCI Synthesis has patents for the synthesis process of amphetamines.

The Department of Justice has issued a final rule to implement Executive Order 14117, which aims to prevent certain countries or individuals from accessing sensitive personal and government-related data of Americans. This rule identifies specific data transactions that are either prohibited or restricted due to national security risks posed by foreign interests. The regulation outlines prohibited data transactions and establishes procedures to authorize or restrict them through licensing. It aims to protect U.S. national security by limiting access to sensitive data by countries considered to be a threat.

The Drug Enforcement Administration (DEA) has revoked the DEA Certificate of Registration for Dr. Shiva Akula after finding that he is not authorized to handle controlled substances in Louisiana, as his medical license is suspended and his controlled substances license is lapsed. The decision follows a Motion for Summary Disposition by the DEA, which Dr. Akula did not respond to, and a recommendation from the Administrative Law Judge supporting the revocation. Consequently, Dr. Akula is also denied any pending applications to renew or modify the registration. This decision was signed by DEA Administrator Anne Milgram and will take effect on January 29, 2025.

The Medical CBRN Defense Consortium (MCDC) has reported changes in its membership to both the Attorney General and the Federal Trade Commission under the National Cooperative Research and Production Act of 1993. This filing intends to continue limiting antitrust plaintiffs to only actual damages in certain situations. New members added to the consortium include Defense Operations & Executions Solutions, Inc. from Florida, Systems & Technology Research from Massachusetts, and The Trustees of the University of Pennsylvania. The group remains open for more members, and further changes in membership will be reported.

The Office on Violence Against Women within the Department of Justice is proposing to extend an existing information collection. They are seeking feedback on the necessity and effectiveness of this information collection, which involves applicants for grants related to the Violence Against Women Act. The information will be used to evaluate and improve grant programs designed to combat domestic violence, dating violence, sexual assault, and stalking. Public comments will be accepted until January 31, 2025.

The Department of Justice's Office of Community Oriented Policing Services is seeking public comments on a new information collection request for the COPS Community Policing Advancement Performance Report. This report is used by law enforcement agencies that receive COPS grant funding. The public has until February 21, 2025, to provide feedback on the proposed collection, which aims to improve community policing. The estimated time for each respondent to complete the application is 11 hours, and participation is voluntary.

The U.S. Department of Justice and the Drug Enforcement Administration took action against Dr. David Bockoff, resulting in the revocation of his license to prescribe controlled substances. This decision came after a hearing revealed he had violated standards of care in prescribing powerful drugs without proper medical examinations or documentation. The government's investigation showed that between January 2020 and June 2022, he frequently prescribed these drugs in a manner inconsistent with both federal and California laws. Dr. Bockoff did not successfully challenge these findings or take responsibility, leading to the conclusion that his practices were dangerous to public health.

ODVA, Inc. has filed notifications with the Attorney General and the Federal Trade Commission about changes in its membership under the National Cooperative Research and Production Act. This filing limits the recovery of antitrust plaintiffs to actual damages in certain situations. New members added to the group include companies from Japan, Malta, the United States, Germany, the United Kingdom, and Sweden, while companies from South Korea and the United States have withdrawn. The membership remains open, and future notifications will be made for any changes.